Improving patient self-management of multiple sclerosis through a disease therapy management program

American Journal of Managed Care

Volumn 16, Issue 2, 2010, Pages 139-144

  Stockl, Karen M ^a   Shin, Jennifer S ^a   Gong, Sherry ^a   Harada, Ann S M ^a   Solow, Brian K ^a   Lew, Heidi C ^a  

^a Prescription Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RELAPSE; SELF CARE; SHORT FORM 12; TREATMENT PLANNING;

EID: 77249108838     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. McAuley E, Motl RW, Morris KS, et al. Enhancing physical activity adherence and well-being in multiple sclerosis: a randomized controlled trial. Mult Scler. 2007;13(5):652-659.
2. Motl RW, Snook EM. Physical activity, self-efficacy, and quality of life in multiple sclerosis. Ann Behav Med. 2008;35(1):111-115.
3. Snook EM, Motl RW. Physical activity behaviors in individuals with multiple sclerosis: roles of overall and specific symptoms, and self-efficacy. J Pain Symptom Manage. 2008;36(1):46-53.
4. Morris KS, McAuley E, Motl RW. Self-efficacy and environmental correlates of physical activity among older women and women with multiple sclerosis. Health Educ Res. 2008;23(4):744-752.
5. Sauter C, Zebenholzer K, Hisakawa J, Zeitlhofer J, Vass K. A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients. Mult Scler. 2008;14(4):500-505.
6. Mathiowetz VG, Matuska KM, Finlayson ML, Luo P, Chen HY. One-year follow-up to a randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Int J Rehabil Res. 2007;30(4):305-313.
7. Bombardier CH, Cunniffe M, Wadhwani R, Gibbons LE, Blake KD, Kraft GH. The efficacy of telephone counseling for health promotion in people with multiple sclerosis: a randomized controlled trial. Arch Phys Med Rehabil. 2008;89(10):1849-1856.
8. Ennis M, Thain J, Boggild M, Baker GA, Young CA. A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. Clin Rehabil. 2006;20(9):783-792.
9. Huyse FJ, Lyons JS, Stiefel FC, et al. "INTERMED": a method to assess health service needs, I: development and reliability. Gen Hosp Psychiatry. 1999;21(1):39-48.
10. Stiefel FC, de Jonge P, Huyse FJ, et al. "INTERMED": a method to assess health service needs, II: results on its validity and clinical use. Gen Hosp Psychiatry. 1999;21(1):49-56.
11. Huyse FJ, Lyons JS, Stiefel FC, Slaets J, de Jonge P, Latour C. Operationalizing the biopsychosocial model: the INTERMED. Psychosomatics. 2001;41(1):5-13.
12. Hoogervorst EL, de Jonge P, Jelles B, et al. The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment. J Neurol Neurosurg Psychiatry. 2003;74(1):20-24.
13. de Jonge P, Hoogervorst EL, Huyse FJ, Polman CH. INTERMED: a measure of biopsychosocial case complexity: one year stability in multiple sclerosis patients. Gen Hosp Psychiatry. 2004;26(2):147-152.
14. Fischer CJ, Stiefel FC, de Jonge P, et al. Case complexity and clinical outcome in diabetes mellitus: a prospective study using the INTERMED. Diabetes Metab. 2000;26(4):295-302.
15. Koch N, Stiefel F, de Jonge P, et al. Identification of case complexity and increased health care utilization in patients with rheumatoid arthritis. Arthritis Rheum. 2001;45(3):216-221.
16. de Jonge P, Latour C, Huyse FJ. Interrater reliability of the INTERMED in a heterogeneous somatic population. J Psychosom Res. 2002;52(1):25-27.
17. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8, pt 2):757-763.
18. Von Korff M, Wagner EH, Saunders K. A Chronic Disease Score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
19. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care. 2000;38(10):1022-1028.
20. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000;57(9):1319-1324.
21. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a Work Productivity and Activity Impairment instrument. Pharmacoeconomics. 1993;4(5):353-365.
22. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the Health Beliefs Model. Mult Scler. 2007;13(9):1146-1152.
23. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):e225.
24. Lafata JE, Cerghet M, Dobie E, et al. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. J Am Pharm Assoc (2003). 2008;48(6):752-757.
25. Rice GP, Oger J, Duquette P, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci. 1999;26(4):276-282.
26. Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler. 2000;6(5):338-342.
27. Nortvedt MW, Riise T, Myhr KM, Nyland HI, Hanestad BR. Type I interferons and the quality of life of multiple sclerosis patients: results from a clinical trial on interferon alfa-2a. Mult Scler. 1999;5(5):317-322.
28. Simone IL, Ceccarelli A, Tortorella C, et al. Influence of interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes. 2006;4:e96.
29. Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon-beta1a (Avonex) treatment. Mult Scler. 2002;8(5):377-381.
30. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilmer T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology. 2002;58(1):37-43.
31. Risman RP, Stockl KM, Liu L. Determining the annual economic impact of multiple sclerosis and characterizing the economic burden of a relapse within a managed care population. Abstract and poster presented at: Academy of Managed Care Pharmacy 20th Annual Meeting and Showcase; April 16-18, 2008; San Francisco, CA.